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One of the main pathogenic effects of severe dengue virus (DENV) infection is a vascular leak syndrome. There are no available
antivirals or specific DENV treatments and without hospital support severe DENV infection can be life-threatening. The cause
of the vascular leakage is permeability changes in the endothelial cells lining the vasculature that are brought about by elevated
vasoactive cytokine and chemokines induced following DENV infection. The source of these altered cytokine and chemokines is
traditionally believed to be from DENV-infected cells such as monocyte/macrophages and dendritic cells. Herein we discuss the
evidence for the endothelium as an additional contributor to inflammatory and innate responses during DENV infection which
may affect endothelial cell function, in particular the ability to maintain vascular integrity. Furthermore, we hypothesise roles
for two factors, sphingosine kinase-1 and microRNAs (miRNAs), with a focus on several candidate miRNAs, which are known to
control normal vascular function and inflammatory responses. Both of these factorsmay be potential therapeutic targets to regulate
inflammation of the endothelium during DENV infection.
1. Introduction
In response to tissue injury or infection the body initiates a
series of cellular events, including (i) vasodilation, (ii) recruit-
ment of neutrophils, (iii) production of vasoactive factors
that will induce endothelial cell (EC) activation, contraction,
and adhesion molecule expression, and (iv) production of
chemotactic factors that will result in recruitment of mono-
cyte/macrophages and lymphocytes from the circulation to
the site of injury. The outcome of these processes is an
induction of a localised inflammatory response that allows
cells to move out of the vessels to the site of injury/infection
to repair cellular damage and restrict the replication of a
pathogen [1]. During a dengue virus (DENV) infection, a
globally significant mosquito borne human pathogen with
an estimated 50–100 million infections per annum, this
normal process has gone awry [2–6]. DENV infection can
be associated with excessive or prolonged inflammatory
responses and EC contraction, permeability, and adhesion
changes of the endothelium [7–11]. These vascular effects of
DENV infection produce a spectrum of severity of disease
with themost severe effects occurring late in infection during
the time of defervescence and decline in viremia [12]. DENV
effects on the vasculature can lead to fluid, protein, and blood
loss from the vessels and bleeding frommucosal surfaces and
sites such as the gastrointestinal tract [12]. In severe cases,
DENV-induced vascular leakage can be life-threatening and
lead to outcomes such as hypovolemic shock (dengue shock
syndrome, DSS) or haemoconcentration and disseminated
intravascular coagulation [4, 9, 12]. There are no antiviral
therapies for DENV and there are only supportive measures
to treat this vascular leak syndrome [13, 14].
While it is clear that the site of severe DENV-induced
pathology is at the vasculature, the contribution of EC to
this pathogenic process is still unclear. In this review we will
discuss the production of inflammatory and innate factors,
including from the EC themselves, during DENV infection.
Moreover, we consider two factors, sphingosine kinase-1
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(SK1) and microRNAs (miRNAs), which are both key to EC
function, vascular integrity, and inflammation, as potential
therapeutic targets to modify the inflammatory response in
the endothelium and alleviate severe DENV pathology.
2. DENV Infection Is Associated with
Altered Production of Inflammatory
and Vasoactive Factors and
Functional Changes to the Endothelium
The lack of widespread damage observed in the endothe-
lium of postmortem DENV patient tissues, in combination
with the ability of patients suffering from severe DENV to
make a rapid and complete recovery, suggests that the loss
of vascular integrity and function during DENV infection
in vivo is not due to major damage to the endothelium.
Instead, these effects are most likely a result of vasoactive
factors released from DENV-infected cells [2, 9, 11]. Cells
contributing to these altered vasoactive factors duringDENV
infection are traditionally thought to be circulating mono-
cytes, tissue macrophages, or dendritic cells (DCs). Mono-
cytes/macrophages and DCs are also major targets for DENV
replication in vivo [15–18]. The role of these DENV-infected
cells as sources of cytokines/chemokines and vasoactive
factors is supported by studies showing altered production
of factors such as interleukin- (IL-) 1, IL-6, macrophage
inhibitory factor (MIF), TNF-𝛼, andmetalloproteinases from
macrophages [19–24] or DC infected with DENV in vitro
[20, 25–27]. Using in vitro models of EC barrier function
based on movement of labelled macromolecules or changes
in cell electrical resistance, soluble factors released from
DENV-infectedmacrophages as well as direct infection of EC
themselves (see Section 3 below) have been shown to induce
permeability changes of an EC monolayer without any asso-
ciated viral-induced cytopathic effect [19, 28–31]. In addition
to factors that induce greater permeability changes, responses
to infection such as production of type I interferon could also
protect or help maintain vascular integrity [32]. Additionally,
DENV infection of EC and endothelial permeability changes
are also associated with alteration of cell surface molecules
on EC such as the upregulation of EC adhesion molecules
(VCAM-1 and ICAM-1) [28, 33] and VEGFR2 [34]. Soluble
VCAM-1 is also reported to circulate at higher levels in
DENV patients [35] and VEGF is elevated in the circulation
of patients with more severe DENV infection [34, 36].
DENV infection of mice deficient in platelet activating factor
receptor (PAFR), a receptor through which PAF can induce
EC permeability changes, resulted in a reduction in DENV-
induced disease without affecting viremia [37]. This suggests
that protection against the DENV-induced effects on the
endothelium can be afforded by reducing the responsiveness
of EC to factors, such as PAF [37]. An interesting set of
experiments by Puerta-Guardo et al. investigatedEC function
in the context of DENV infection of differentiated monocytic
cells in the presence of a monoclonal antibody to DENV
protein E [38]. Monocytic cells infected with DENV in
the presence of the antibody produced significantly higher
levels of the inflammatory cytokines TNF-𝛼 and IL-6 than
cells infected in the absence of antibody. Exposure of EC
monolayers to conditioned medium from the monocytes
(infected with DENV in the presence of antibody) leads to
rapid degradation in EC barrier function that was shown
to be mediated by TNF-𝛼, IL-6, and IL-12p70. Additionally,
injection of the conditioned medium into mice resulted
in increased vascular permeability in the lungs and sera,
supporting the notion that factors released from DENV-
infectedmonocyte/macrophages have a clear role in inducing
the deleterious effects of DENV on the vasculature and
suggesting that antibody-dependent enhancement plays a
role in severe dengue infection pathologies.
In addition to macrophages and DC, other cell types
such as mast cells [39, 40] and platelets [41] can produce
vasoactive factors such as VEGF which influence EC acti-
vation and function. Furthermore, microarray analysis of
peripheral blood mononuclear cells (PBMCs) from DENV-
infected patients indicates upregulation of transcripts from
interferon-stimulated and neutrophil-associated pathways
and a correlation of these transcriptional changeswith disease
severity [42].
Levels of factors such as VEGF [34, 36], IL-6, IL-8,
IFN-𝛽 [43, 44], and TNF-𝛼 [33, 45, 46] in the circulation
of DENV-infected patients are positively associated with
disease severity. Interestingly, elevatedMIP-1𝛽 and IL-12 were
associatedwith improved disease outcomes [47] and similarly
higher levels of IL-12 are seen in patients with mild but not
severe disease [48].
Taken together, these studies demonstrate that there are
changes in the production of many factors released from the
different cell types that are altered during a DENV infection
and that these probably act in concert to induce inflammation
and functional changes in the endothelium.
3. Endothelial Cells Are a Source of
Inflammatory and Vasoactive
Responses during DENV Infection
In addition to the production of factors cited above, altered
production of cytokine, chemokine, and vasoactive factors
by EC themselves may also arise from the DENV infection.
Numerous studies using cell lines and primary EC sources
have shown that EC are targets for DENV infection in
vitro [32, 44, 49–57]. Analysis of postmortem tissue from
human DENV infection, however, does not support a gen-
eralised DENV EC infection, although DENV replication
has been identified in some EC [58–60]. DENV-infected
EC in vitro show altered production of factors such as
IL-8 and complement [50], IL-6, and tissue plasminogen
activator (TPA) [31, 43, 44]. mRNA expression analyses
in EC challenged with DENV have shown induction of
a number of pathways in response to infection, including
components of the dsRNApathway/interferon response, such
as OAS and MxA, and inflammation, such as TNF-𝛼 [56,
61]. Microarray analysis of DENV-infected human umbilical
vein EC (HUVEC), in a model where more than 80% of
the cells are infected, has demonstrated large increases in
expression of cytokines (including CXCL9/10/11 and IL-7),
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complement factors, IFN-𝛽, and IFN-inducible genes such
as viperin at 24 hours after infection [62]. In this study, the
expression of inflammatory cytokines and chemokines was
demonstrated to be dependent on IFN-𝛽 and not IFN-𝛼
release from EC [62]. Our own studies have similarly shown
IFN-𝛽 dependent induction of innate antiviral responses via
induction of mRNA for interferon stimulated genes (ISG)
such as viperin, OAS1, and IFIT-1 in DENV-infected EC
[55]. Other studies have demonstrated RIG-I dependent
induction of interferon and inflammatory cytokines, includ-
ing IFN-𝛽, IL-6, IL-8, and RANTES, from DENV-infected
EC [53]. Knockdown of RIG-I expression did not affect
DENV replication, prompting the authors to suggest that
RIG-I dependent cytokine and adhesionmolecule expression
contributes to DENV pathogenesis through promotion of the
inflammation response (via leukocyte recruitment to EC).
In our DENV EC infection model, using primary HUVEC,
only a small proportion of EC become infected, but this has
major consequences for the ability of EC to maintain normal
barrier function in vitro, particularly following exposure to
TNF-𝛼 [55]. These in vitro studies demonstrate that EC
can become DENV-infected resulting in type 1 interferon
responses and production of inflammatory factors that have
vasoactive properties. Production of these factors from the
EC themselves may act in an autocrine/paracrine manner
to have larger and measurable functional changes on the
endothelium as a whole.
Important roles for EC in viral induced inflammatory
responses are also supported bymousemodels of infection. In
a mouse model of dengue haemorrhage, DENV inoculation
resulted in DENV-infected EC, increased TNF-𝛼 production,
macrophage recruitment, and EC apoptosis [63, 64]. In
this model, TNF-𝛼 production originated from infiltrating
macrophages. EC in the haemorrhage tissues were DENV-
infected and demonstrated TNF-𝛼-enhanced production of
reactive nitrogen and oxygen species, contributors to EC
apoptosis and EC barrier damage. A study by Zellweger
et al. also demonstrated that a mouse model of antibody-
dependent enhancement of DENV infection causes a more
severe DENV disease and is also associated with DENV
infection of EC in the liver [65]. Mouse models for infections
with other viruses have also shown EC to have a key role
in inflammation. Studies of influenza A virus (IAV) have
also shown that the respiratory endothelium is key to the
inflammatory response and induction of cell infiltration in a
mouse model of highly pathogenic IAV [66]. This response
was mediated by sphingosine-1-phosphate (S1P) receptor 1
(S1PR1) on EC. Agonism of S1PR1 on EC suppressed cytokine
and chemokine production, including IFN-𝛼, TNF-𝛼, and
IL-6. In a primate model of hantavirus pneumonia, the
respiratory endothelium is the main site for host immune
responses to infection also suggesting broader roles for
EC during inflammatory responses to viral infections [67].
While, as described above, postmortem analysis of human
DENV-infected tissues has shown some evidence of DENV
infection of EC, analysis of the inflammatory response in
these tissue samples has not been addressed but may yield
insight into similar roles of the endothelium in inflammation
during DENV infection in vivo.
Thus, traditionally, it has been considered that mono-
cyte/macrophages and DCs are the main contributors to
altered cytokines/chemokines and vasoactive factors that
affect the endothelium during DENV infection, but growing
evidence suggests that the EC themselves may also play an
important role in propagating this dysregulated proinflam-
matory process.
4. SK1 Is a Key Regulator of
Vascular Integrity and Inflammation and
Is Altered during DENV Infection
Sphingosine kinase is a cellular lipid kinase that phosphory-
lates the lipid sphingosine to form S1P. One important role
of SK1 is in control of the cell survival-death balance or
rheostat [68]. Additionally, SK1 and S1P have vital functions
in maintenance of EC permeability and vascular integrity
[69] as well as EC functions including modulation of cell
adhesion molecule expression [70] and adhesion-mediated
cell survival [71]. SK1 has also been described as an important
intracellular component of cell signaling pathways [72], in
particular the pathway for TNF-𝛼 stimulated activation of
NF𝜅B [73, 74], a vital transcription factor for induction
of many inflammatory factors [75]. The roles of SK1 and
S1P in inflammation have been recently reviewed [76, 77].
Our studies have shown that SK1 is reduced late in DENV
infection in a variety of different cell lines, leading to reduced
TNF-𝛼 stimulated NF𝜅B activation [78, 79]. In contrast, early
in DENV infection of EC, SK1 activity is increased and this
is associated with enhanced TNF-𝛼 induced permeability of
EC [55], consistent with reported sensitization of EC to TNF-
𝛼 by overexpression of SK1 [80]. SK1 is also required for IL-1
stimulated IRF1 mediated production of chemokines such as
CXCL10 and IL-6 [81]. Both TNF-𝛼 and IL-1 are prototype
stimuli for type II activation of EC, resulting in NF𝜅B
activation, production of inflammatory factors, increased
adhesion molecule expression, and increased permeability of
EC [1].Thus, SK1 can be altered byDENV infection in EC and
this will have consequences for responses to inflammatory
and vasoactive mediators such as TNF-𝛼 and maintenance of
vascular integrity.
4.1. Can We Target SK1 Activity in the Endothelium to
Reduce DENV-Induced Permeability of the Vasculature? As
stated above, growing evidence suggests a positive association
between SK1 activity and TNF-𝛼 responses. Additionally,
reports show that TNF-𝛼 is strongly linked to DENV disease
in mice [63, 64]. TNF-𝛼 antibody can reduce the DENV-
induced lethality in mice [82] and high levels of TNF-𝛼
in the circulation correlate with disease severity in humans
[45, 46]. Therefore, inhibiting SK1 activity may prevent the
pathogenic effects of TNF-𝛼 actions on the EC during DENV
infection, as outlined in Figure 1. SK inhibitors are in devel-
opment as anticancer therapeutics [83, 84] and perhaps these
could be investigated for DENV treatment. Although this
would require a fine therapeutic balance between inhibition
of the deleterious role for SK1 in promoting inflamma-
tory responses, whilst maintaining essential roles of SK1 in
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Figure 1: TNF-𝛼 or VEGF-mediated NF𝜅B activation promotes inflammation and opening up of EC junctions leading to increased vascular
permeability. Increased VCAM-1 is associated with altered EC function and recruitment of immune cells. We propose (A) Inhibition of SK1.
(B) Increased miRNA levels will reduce TNF-𝛼 or VEGF-mediated NF𝜅B activation and reduce VCAM-1 expression leading to maintenance
or improvement of vascular integrity.
maintaining vascular integrity, the use of SK1 inhibitors has
been shown to inhibit the induction of EC permeability by
thrombin and neutrophils in an in vitro model and thus
this selectivity of action is feasible [85]. Furthermore, recent
advances in the selective targeting of inhibitors specifically to
cytokine-activated EC have shown success in reducing NF𝜅B
activation in vivo [86]. This suggests that a similar approach
may be possible for targeting SK1 in these cells during the
activation of EC associated with DENV infection.
S1P can act as a bioactive sphingolipid in signaling
pathways inside cells or can be secreted from cells and act
on a family of S1P receptors (S1P
1–5) [87, 88]. S1P levels have
recently been reported to be reduced in the circulation of
DENV patients and thus may influence vascular integrity
[89]. A number of agents are currently in development
to modulate the SK/S1P axis by agonising or antagonising
specific S1P receptors [90–92]. As discussed earlier, agonism
of S1P receptors in EC suppresses cytokine and chemokine
production [66], while S1P itself has been shown to alleviate
the EC permeability induced by Hantavirus infection in vitro
[93]. FTY720 is an agent that modulates all S1P receptors,
except S1P receptor-2, and is already in clinical use for
multiple sclerosis (MS) due to its lymphopenia-inducing
properties [94]. FTY720 can block TNF-𝛼 induced EC
permeability in vitro. Indeed, through its agonism of S1PR1,
FTY720-mediated increased endothelial barrier function has
been proposed as onemechanismwhereby this agent inhibits
lymphocyte egress from lymph tissue [95, 96]. Similarly, use
of S1PR1 agonists such as FTY720 could be of benefit to pro-
tect the vasculature against the TNF-𝛼mediated induction of
EC permeability during DENV infection.
5. MicroRNAs: An Additional Mediator of
EC Inflammation during DENV Infection?
First discovered in 1993, miRNAs are a class of noncoding
RNA with a length of around 22 nucleotides [97]. The
expression, processing, and specific mechanisms by which
this highly conserved and important class of molecules
functions has been well reviewed elsewhere [98]. Through
mRNA binding and subsequent inhibition of translation
and/or induction of mRNA degradation, miRNAs fine-tune
the expression of cellular genes making them key regu-
lators of numerous cellular processes. It is estimated that
at least 60% of protein coding genes have miRNA target
sites in the 3󸀠-untranslated regions (UTRs) of their encoded
mRNAs and a single miRNA can regulate translation of
hundreds of genes [99]. miRNAs have well established roles
in endothelial cell inflammation but substantially less is
known about the relationship between miRNAs and DENV-
induced EC inflammation and reduced vascular integrity
or, indeed, about miRNAs and DENV replication itself.
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To date there is little knowledge regarding modification of
miRNA expression in DENV-infected EC and the possibility
of miRNA transfer, for example, through exosomes, between
DENV-infected monocytes/macrophages and EC has not
been investigated. Additionally, the inflammatory stimuli,
such as IFNs, TLR ligands, and chemokines, secreted from
DENV-infected monocytes, macrophages, and DC, would
certainly induce changes in miRNA levels in EC but this
also has not been specifically investigated in the context
of DENV infection, for example, through the use of cell
coculture techniques or application of supernatant from
DENV-infected immune cells to cultured EC.
DENV infection, however, has been shown to modulate
the abundance of a variety ofmiRNAs in nonendothelial cells.
Although not specifically the subject of this review, these
studies highlight the connection between DENV replication
and miRNAs and, furthermore, changes in miRNA abun-
dance in these cells contribute to the release of inflammatory
stimuli, which would subsequently influence EC inflamma-
tion.
5.1. DENV Infection and miRNA Expression Changes in Non-
EC Sources. Microarray analysis of miRNA levels in whole
blood of patients at various stages after DENV infection (up
to 14 days after infection) compared to uninfected patients
detected a total of 348 miRNAs which were differentially
expressed [100]. Groups of miRNAs were found to be specifi-
cally differentially regulated at the various stages of infection
presenting the possibility that some of these miRNAs may
be useful as biomarkers of infection progression or of DENV
infection itself. Indeed, 3 miRNAs, miR-24-1-5p, miR-512-5p,
and miR-4640-3p, were found to be differentially regulated
following DENV but not IAV infection. Of the many differ-
entially regulated miRNAs in DENV-infected patients, none
appear to have well-known roles in EC inflammation or bar-
rier integrity, although miR-299-3p which was upregulated
in all DENV-positive patients is known to play a role in EC
senescence [101].
Changes in the abundance of miRNAs in DENV-infected
PBMCs have also been observed by microarray analysis of
infected cells [102]. Qi et al. observed significant changes in
19 miRNAs with the most significant change in expression
levels observed for miR-4290, miR-1290, miR-33a, and miR-
let-7e (upregulated) and miR-106b, miR-20a, and miR-30b
(downregulated). Target prediction suggested that miR-let-
7e may target the UTR of IL-6 and CCL3, while miR-
451 and miR-106b could potentially target MIF and CCL5,
and miR-4279 could potentially target CXCL1. Functional
demonstration of these mRNAs as miRNA targets was not
conducted, however, nor has it been reported elsewhere. A
specific investigation into the role of these miRNA alter-
ations in DENV-induced changes in PBMCs, in particular
if they have any relationship with the chemokine release
(especially CCL5, IL-6, and IL-8) that was observed from
DENV-infected PBMCs in this same study, has not been
examined [102]. The majority of the miRNAs differentially
regulated in DENV-infected PBMCs have been implicated in
other cellular processes and disease states including cancer
(e.g., miR-1290), mitochondrial function (e.g., miR-33a), and
apoptosis (miR-106b) and may be related to similar changes
in cell growth during a DENV infection [103–105].
Zhu et al. specifically investigated the role a of a sin-
gle miRNA, miR-30e∗, in DENV-1, -2, or -3 infection of
HeLa cells [106]. Following DENV infection, increased lev-
els of miR-30e∗ were observed. Furthermore, U937, HeLa,
or PBMC cells transfected with miR-30e∗ demonstrated
increased IFN-𝛽, OAS1, MxA, and IFITM1 production (com-
pared to cells transfected with a negative control mimic).
Induction of IFN-𝛽 appeared to occur through a direct
interaction of miR-30e∗ with the 3󸀠-UTR of I𝜅𝛽𝛼 resulting
in a decrease in cellular levels of I𝜅𝛽𝛼. Reduced levels of
I𝜅𝛽𝛼 would subsequently lead to activation of NF𝜅B and
induction of IFN-𝛽. Thus when U937, HeLa, and PBMC cells
were transfected with miR-30e∗, DENV-2 replication was
inhibited. Potentially, targeted delivery ofmiR-30e∗ to PBMC
could represent a therapeutic strategy for inhibiting DENV
infection.
A broader role for DENV infection in miRNA modula-
tion was observed by Kakumani et al. who demonstrated that
DENV infection of Huh7 cells resulted in a decrease in the
mRNA levels of miRNA processing proteins, includingDicer,
and a subsequent downregulation of 143 of the 151 miRNAs
randomly investigated [107]. The inhibition of miRNA pro-
duction was, at least in part, mediated by the middle and C-
terminal domains of the DENV protein, NS4B, suggesting
a direct ability of DENV to modulate the cellular proteins
involved in miRNA synthesis.
In contrast to these studies, a general role for miRNAs
in regulating virus replication, including DENV, has been
questioned [108]. Knockout of themiRNAprocessing protein
Dicer from 293T cells, which renders them incapable of
producing mature miRNA (or siRNA), did not significantly
alter the replication of 10 different test viruses. Interestingly,
however, of the 10 viruses investigated in this study, DENV
was the only one to show a reproducible lower level of
replication in the Dicer-negative cells, which could not be
attributed to slower cell growth.
Overall, however, there is an abundance of evidence
demonstrating that DENV infection modulated miRNA lev-
els in a variety of cell types. No studies were conducted in EC
however, and thus any relationship that miRNAs identified
above have with DENV-induced EC inflammation or barrier
integritywould be indirect. For example, in the studies of Jong
et al. and Qi et al. in blood or PBMC, the analysed samples
would not contain any intracellular EC-associated miRNAs.
Any potential contribution of EC-derived miRNA to the cir-
culation could only have arisen from miRNAs secreted from
the EC (e.g., in exosomes) or from circulating EC, which have
been observed in patients with severe DENV disease [35]. In
relation to the circulating changes in miRNAs that have been
observed, if the upregulation ofmiR-let-7e documented byQi
et al., for instance, did indeed modulate PBMC production
of IL-6, this may subsequently promote EC inflammation
[102]. In particular, it is interesting to speculate on a role
for miR-30e∗, which, as discussed, can influence interferon
responses, in DENV-induced modulation of EC function as
well as DENV infection of EC. Furthermore, we and others
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have demonstrated that IFN-𝛽 is induced in DENV-infected
EC [8, 55]. It would be interesting to investigate the role
of miR-30e∗ in both EC function and interferon responses
either following direct infection of EC or in EC that have been
exposed to, for example, supernatant from DENV-infected
PBMC or macrophages.
5.2. miRNAs That May Contribute to EC Inflammation and
Barrier Integrity during DENV Infection. The role of miR-
NAs in EC inflammation and barrier integrity is very well
established and there are several excellent reviews on the
topic [109–111]. However, there has been little investigation
into changes in EC miRNA levels during DENV infection.
Here we will focus on a few miRNAs that may be of
particular interest, given their well-established role in EC
inflammation and barrier integrity in other physiological
states. Inflammatory stimuli such a IFNs, lysophosphatidic
acid (LPA), ILs, TNFs, and TLR ligands, which are induced
by DENV infection, are known to alter expression of several
miRNAs in EC including, but not limited to, miR-223, miR-
126, miR-155, andmiR-221/222 [109–111]. Here wewill discuss
the known functions of these miRNAs in EC function and
their potential role in DENV infection.
5.2.1. miR-223. Recently, DENV-induced regulation of a
miRNA in EC was in fact demonstrated, although not
in the context of EC inflammation and barrier integrity
[112]. Detailed work by Wu et al. demonstrated that miR-
223 was downregulated in EAhy926 cells (cultured human
vascular endothelial cells) following DENV infection, while
EAhy926 cells transfected with a miR-223 expression vec-
tor had reduced DENV replication [112]. Further analysis,
based on target prediction of miR-223, showed that miR-223
inhibits translation of themicrotubule destabilizer, stathmin-
1. Stathmin-1 was shown to be upregulated following DENV
infection of EAhy926, while inhibition of stathmin-1 expres-
sion had a negative effect on DENV replication.Thus, DENV
infection of EAhy926 cells decreased expression of miR-
223, resulting in an increase in stathmin-1 transcription and
protein levels, which assists DENV replication through an
as yet unknown mechanism. While the miR-223/stathmin-1
link described in the study of Wu et al. does not specifically
link to any particular EC state, it does link DENV replication
to miRNA function. Furthermore, miR-223 does have well-
established roles in inflammation in the context of other
cell types, in particular adipocytes (reviewed in [113]). In
this context, miR-223 downregulation is associated with
increased inflammation and thus it is plausible that miR-
223 downregulation in DENV-infected EAhy926 cells may
similarly contribute to induction of proinflammatory stimuli
in these cells [113]. This is a new and developing area of
EC biology and, of note, high EC levels of miR-223 in vitro
have been only recently reported likely due to the fact that
miR-223 levels rapidly decreased when primary cells were
cultured [114]. Interestingly, miR-223 can be transferred in
microvesicles from activated platelets to EC, suggesting that
circulating cells could modulate EC function by transfer of
miR-223 [115].
5.2.2. miR-126. miR-126 is one of the most abundantly
expressed miRNAs in EC and is known to be involved
in the inflammatory response, angiogenesis, and vascular
integrity [116–118]. Expression of miR-126 is regulated by the
transcription factor E26 transformation-specific sequence-
1 and -2 (Ets-1 and Ets-2, further discussed below) [119].
Both Ets-1 and Ets-2(−/−) and miR-126(−/−) mice show a
similar phenotype of impaired vascular formation and partial
lethality [117, 118, 120, 121]. miR-126 represses the translation
or degrades the mRNA of three key EC genes involved in
vascular integrity and inflammation: SPRED1, PI3KR2, and
VCAM-1 [117, 118, 122]. SPRED1 is a negative regulator of
theMAP kinase pathway and interacts with testicular protein
kinase-1 (TESK-1) to prevent the phosphorylation of cofilin
[117, 118, 123, 124]. Unphosphorylated cofilin leads to dis-
rupted adherens junctions and contributes to an increase in
EC permeability. Overexpression of SPRED1 or knockdown
of miR-126 also decreases responsiveness to VEGF, a factor
crucial in maintaining EC permeability. Likewise, PI3KR2, a
negative regulator of the PI3 kinase pathway, inhibits VEGF
induced vascular integrity.The roles ofmiR-126 in EC perme-
ability are summarised in Figures 2 and 3.miR-126 suppresses
VCAM-1 levels and therefore is important in preventing
initiation of inflammation in resting EC (Figure 3) [122].
Additionally, Ets-1, a transcriptional activator of miR-126,
induces VCAM-1 expression in response to proinflammatory
mediators. This coalesces as a neatly regulated negative
feedback process by which VCAM-1 mediated inflammation
can be controlled: Ets-1 induces VCAM-1 and miR-126, with
miR-126 subsequently reducing transcription of VCAM-1
[119].
miR-126 also has a role in the innate responses of pDCs,
with miR-126(−/−) mice showing increased pDC apoptosis
resulting in fewer circulating pDCs [125]. Those remaining
pDCs have impaired function including reduced ability to
produce IFN-𝛽 and IFN-𝛼 and to migrate to lymphoid
tissues. Additionally, miR-126 was found to be a positive
regulator of Kdr, the gene which encodes VEGFR2 in mice
[125]. Therefore changes in the levels of miR-126 in DENV-
infected pDCs are likely to contribute to EC inflammation
through IFN-induced mechanisms.
5.2.3. miR-155. A role for miR-155 in inflammation was
first demonstrated by its upregulation in macrophages
treated with either polyriboinosinic:polyribocytidylic acid
(poly(I:C)) or IFN-𝛽 or TLR ligands [126]. miR-155 is abun-
dant in EC and has been demonstrated to be crucial in TNF-𝛼
induced downregulation of endothelial nitric oxide synthase
(eNOS), a regulator of EC permeability [127, 128]. In HUVEC
cells, TNF-𝛼 was shown to induce miR-155 expression which
subsequently bound to the 3󸀠UTRof eNOSmRNA, inhibiting
its translation. Sun et al. investigated this in relation to cardio-
vascular disease and, in this regard, reported that simvastatin
treatment of HUVECs prevented TNF-𝛼 induced downregu-
lation of eNOS and reduced TNF-𝛼 induced miR-155 expres-
sion. As eNOS (and NO it produces) is a regulator of EC
permeability, it would be interesting to investigate miR-155
abundance and any subsequent changes in TNF-𝛼 induced
eNOS expression in the context of DENV infection [129].
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Figure 2: Roles of miR-126, miR-155, miR-221, and miR-222 in endothelial cell inflammation and maintenance of vascular integrity. (a)
miR-126 regulates EC permeability through inhibition of PI3K andMAPK signaling pathways. miR-126 regulation of SPRED1 also indirectly
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Interestingly, our ownmicroarray analysis of DENV-infected
murine embryonic fibroblasts (MEF) suggests that miR-
155 is upregulated following DENV infection (Carr, unpub-
lished observations). miR-155 has also been shown to reduce
expression of the angiotensin-II (AngII) type-1 receptor
(AT1R), resulting in a decrease in AngII-induced expression
of VCAM-1, monocyte chemoattractant protein-1 (MCP-1),
and vascular endothelial growth factor receptor (VEGFR1)
and, ultimately, reducing T-cell recruitment [128].These roles
for miR-155 are summarized in Figure 2(c).
5.2.4. miR-221/222. miRNAs miR-221 and miR-222 are often
grouped together when studied (miR-221/222) due to the fact
that their expression is likely to be simultaneously regulated
and they are located close together on chromosome Xp11.3
[130]. miR-221 and to a lesser extent miR-222 are known
to regulate ICAM-1 expression in EC in response to viral
infection (Figure 2(d)) [131]. In HUVECs, the HIV protein
Tat induces a downregulation in the expression of both miR-
221 and miR-222, which leads to an increase in ICAM-
1 expression and recruitment of monocytes. The reduction
in both miR-221 and miR-222 levels and the increase in
ICAM-1were associatedwith activation of theNF𝜅Bpathway.
miR-221 has also been shown to downregulate expression
of adiponectin receptor 1 (AdipoR1) in HUVECs, which
subsequently inhibits NO production [132].
5.3. The Potential for Coregulation of miR-126, miR-155, and
miR-221/222 during DENV Infection. Particularly interesting
is the fact that miR-126, miR-155, and miR-221/222 share a
regulation pathway involving Ets-1, a transcription factor that
is important in EC inflammation [133, 134]. Transcription
of Ets-1 itself can be induced by variety of proinflammatory
stimuli including AngII, IL1-𝛽, and TNF-𝛼 (reviewed in
[134]). For example, in C57BL/6 mice, Ets-1 expression is
initiated rapidly following activation of mouse aortic vas-
cular smooth muscle and EC with AngII and leads to an
increase in translation ofMCP-1, the cyclin-dependent kinase
inhibitor P21CIP, plasminogen activator inhibitor-1 (PAI-1),
and VCAM-1 [133]. While MCP-1 and VCAM-1 contribute
to monocyte recruitment to the EC, P21CIP was shown to
be associated with EC apoptosis [133]. PAI-1 inhibits the
generation of proteins (e.g., plasmin) involved in remodeling
of the extracellular matrix and thereby contributes to fibrosis.
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cell recruitment. miR-155 and miR-221/222 act to reduce translation
of Ets-1, while miR-126 acts further downstream to reduce VCAM-1
translation.
The link between miR-126, miR-155, miR-221/222, Ets-1, and
the roles of these factors in EC function is complex but is
simplistically summarised in Figure 3. Firstly, the transcrip-
tion of miR-126 is positively regulated by Ets-1 which, in turn,
is negatively regulated by miR-221/222 and miR-155. As dis-
cussed, induction of all of these factors occurs in the presence
of proinflammatory stimuli including TNF-𝛼 (e.g., miR-155
and Ets-1), foreign antigens (e.g., miR-221/222), IFN-𝛽 (e.g.,
Ets-1 and miR-126), and AngII (e.g., miR-155). Subsequently
the transcription of a variety of proinflammatory and EC
regulatory mediators is further induced, including VCAM-1,
MCP-1, and P21CIP. miR-155, miR-221/222, and miR-126 act
to reduce the transcription of these proinflammatory stimuli.
Several of the proinflammatory mediators regulated by
miR-126, miR-155, and miR-221/222 are known to be upregu-
lated following DENV infection either in in vitro EC studies
or in patient sera. MCP-1 is known to be highly expressed
in patients with severe DENV disease (with hemorrhagic
fever and shock syndrome), although the pathways leading
to its high expression have not been investigated [135]. MCP-
1 transcription can be induced by IL-1𝛽 and TNF-𝛼 and
regulated by NF𝜅B and activator protein 1 (AP-1) or, as
discussed above, in EC it can be induced by AngII and
regulated by Ets-1 [133, 136]. It is interesting too to note that
treatment of mice with the AngII type-1 receptor (AT1R)
antagonist Losartan prior to DENV infection resulted in a
decrease in DENV antigen presentingmacrophages as well as
a decrease in IL-1 production, compared to untreated,DENV-
infected mice [137]. As discussed, soluble ICAM-1, soluble
VCAM-1, and circulating EC are altered in the peripheral
blood of patients with severe dengue infection [35]. In vitro,
exposure of EC to culture medium from DENV-infected
monocytes results in a TNF-𝛼 mediated increase in VCAM-
1 and ICAM-1 expression in the EC [28]. Although reports
describing the relationship between DENV infection and
serum VEGF levels have been conflicting, higher levels of
soluble VEGFR1 are commonly reported in dengue-infected
patients and may also be correlated with disease severity
[28, 138].
Finally, there is precedent for regulation of miR-155, miR-
126, and miR-222 in virus-infected EC. Andes hantavirus
(ANDV), a virus that can also lead to hemorrhagic fever
and vascular leakage in vivo, results in significant changes
in the abundance of 23 miRNAs in infected HUVECs,
including miR-155, miR-126, and miR-222 [139]. Following
ANDV infection of HUVEC levels of miR-155 increased
sixfold, while miR-222 levels increased threefold. Although
miR-126 levels appeared to show a small (twofold) increase
following ANDV infection, SPRED1 and PIK3R2 mRNA lev-
els (see Section 5.2.2) were increased tenfold and sevenfold,
respectively.This is unexpected given thatmiR-126 negatively
regulates SPRED1 and PIK3R2 transcription and the authors
concluded that ANDV interferes with miR-126 by an as yet
unknown mechanism. Potentially too, the increase in miR-
126 levels was not sufficient to regulate SPRED1 and PIK3R2
mRNAs, and indeed the abundance of miR-155 would act as
a negative regulator of miR-126 transcription (Figure 3). It is
likely that with more research more roles for these miRNAs
in EC function during viral infection and inflammation will
be uncovered to expand the complex interactions depicted in
Figure 3.
From the proceeding discussion it can be seen that DENV
modulation of ECmiRNA levels is highly probable and likely
to go beyond the only report so far of miRNA modulation
in DENV-infected EC [112]. Whether miRNA modulation
in EC is a result of DENV infection of the EC themselves
or activation of EC by stimuli released from DENV-infected
monocytes, macrophages or pDCs is, in some regards, irrel-
evant. One might predict a simple model whereby at time
points early after DENV infection levels of, for example,
the miRNAs discussed here may be reduced thereby releas-
ing inhibition of the inflammatory response. In a resolved
course of infection, restoration of normal EC miRNA levels
would occur. In situations of prolonged reduction of these
miRNA levels, we would also anticipate prolonged and
increased levels of factors with known inflammatory and
EC permeability increasing properties such as VCAM-1 and
PI3K. Such an extended reduction of miRNA levels in EC
that control inflammation and EC permeability may be an
important contributor to the reduced vascular integrity and
uncontrolled inflammation seen late in DENV infection
with accompanying severe DENV disease. Potentially, direct
infection of EC could contribute to decreased miRNA levels
through sequestration of the miRNA, in a similar manner to
HCV interaction with miR-122 [140]. Although this simple
model is appealing, themechanisms are likely more complex.
Importantly, if a role for miRNAs in DENV pathogenesis
could be identified, it may present a target for antiviral
miRNA enantiomers or delivery of miRNA mimics which
may help to control the inflammation and vascular per-
meability that occurs in late-stage, severe DENV infection
and limit postinfection progression of inflammation. There
are several methods by which miRNAs can be delivered,
including somewhich can specifically target EC [141–143] and
the exciting potential to understand the role ofmiRNAs in EC
function during DENV infection remains to be explored.
Mediators of Inflammation 9
6. Summary and Perspective
Evidence demonstrates that severe DENV can be consid-
ered as an infectious trigger of an acute vascular disorder
associated with an inflammatory process. The inflammatory
process may be driven, at least in part, by responses of
the endothelium itself to infection. There are currently no
clinically available antiviral treatments to reduce DENV
replication, and treatment of the DENV vascular leak syn-
drome is by supportive measures only. By understanding the
factors driving the inflammatory process and responses of the
EC to DENV, we have rationalized new potential therapeutic
targets, SK1 and miR-126, miR-155, and miR-221/222, to treat
the severe symptoms of DENV infection. A key factor for
success of these potential therapies aimed at the process
of inflammation may be the timing of administration of
treatment. Vascular leak syndrome typically occurs late in
infection, after viremia decline, and at this stage of infection
it may be clinically safe to dampen down the inflammatory
factors affecting the vasculature without the risk of exacer-
bating DENV infection via any immunosuppressive effects.
Additionally, in accordance with WHO 2009 guidelines,
patients now may be classified as DENV with or without
warning signs, with the former at highest risk of development
of severe DENV. These patients may be an important target
group for therapy to modulate molecules in the EC and thus
to ensure vascular integrity is maintained and attenuate the
onset of life-threatening DENV-induced disease.
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